



GOVERNMENT OF INDIA
CENTRAL DRUGS STANDARD CONTROL
ORGANISATION (Headquarter)
(Directorate General of Health Services)
Ministry of Health & Family Welfare
FDA Bhavan
ITO, Kotla Road
New Delhi - 110002 (Delhi)
Phone No.: 91-11-23216367
Fax No.: 91-11-23236973
E-Mail : dci@nic.in

File No. CT/23/000056

To,

M/s. Novo Nordisk India Pvt. Ltd.,
Plot No.32, 47-50, EPIP Area, Whitefield,
Bangalore, Karnataka (India) – 560066.

Sir,

With reference to your application No. GCT/CT04/FF/2023/37706 (GCT/56/23) dated 22-05-2023, please find enclosed herewith the permission in Form CT-06 for conduct of Phase 3b clinical trial titled, **“A 40-week study comparing the efficacy and safety of once weekly IcoSema and daily insulin glargine 100 units/mL in participants with type 2 diabetes inadequately controlled on oral anti-diabetic drugs COMBINE 4”** Protocol Number: NN1535-4988, Protocol Version 1.0, Final dated 12-April-2023 with a total of up-to 100 subjects from India under the provisions of New Drugs and Clinical Trial Rules, 2019

The permission granted by the Central Licensing Authority to conduct clinical trial shall be subject to following conditions, namely:-

- 1) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under rule 8;
- 2) where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:
Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:
Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;
- 3) in case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- 4) the Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

- 5) clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- 6) clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- 7) status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- 8) six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority electronically in the SUGAM portal;
- 9) in case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;
- 10) any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;
- 11) in case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;
- 12) in case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;
- 13) the premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- 14) where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;
- 15) the laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;
- 16) the Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- 17) the sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

- 18)** Merely granting permission to conduct the clinical trial with the Investigational Drug Product does not convey or imply that, based on the clinical trial study data generated with the investigational drug, permission to market this drug in the country will automatically be granted to you;
- 19)** The permission to initiate clinical trial granted under rule 22 in form CT-06 or automatic approval under rule 23 in Form CT 4A shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Yours faithfully,

RAJEEV SINGH
RAGHUVANSHI
I (Dr. Rajeev Singh Raghuvarshi)
Drugs Controller General (India) &
Central Licencing Authority
Stamp

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL
ORGANIZATION, ou=RAJEEV SINGH RAGHUVANSHI,
2.5.4.20=80x276a23e4eafbe8a239774cdeb63c27690
41015a055564e6c7f54b755db1c2,
postalCode=600034, st=TAMIL NADU,
serialNumber=657F5E47D946985C8F0388DC302DDE1
Date: 2023.04.23 12:44:34 +05'30'

FORM CT-06

(See rules 22,25,26,29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

1. The Central Licensing Authority hereby permits **M/s. Novo Nordisk India Pvt. Ltd., Plot No. 32, 47 - 50, EPIP Area, Whitefield Bangalore (India) - 560066** to conduct clinical trial of the new drug or investigational new drug as per **Protocol Number: NN1535-4988, Protocol Version 1.0, Final dated 12-April-2023** in the below mentioned clinical trial sites [As per Annexure].-
2. Details of new drug or investigational new drug and clinical trial site [As per Annexure].
3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi

Date _____

RAJEEV SINGH

RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD
CONTROL ORGANIZATION, ou=RAJEEV SINGH
RAGHUWANSHI,
2.5.4.20=80c62f6a23caefba9a239774cdcb03
c2269e9dfe9bf76cc5baf37cfadbbda
postalCode=600034, st=TAMIL NADU,
serialNumber=6521B547D4A996F6EBCDDC
02DDE1FC3APAT2A1A12be9a9fa3107e734d1

(Dr.) Rajeev Singh Raghuvanshi)
**District Controller General (India) &
Central Drug Authority**

Digitally signed by RAJEEV SINGH
RAGHUVAHSNI
DN: c=IN, o=CENTRAL TRUSTS STANDARD
RAJEEV Singh Raghuv
2.5.4.20=80c62f6a23e4afbe8a239774cdcb03
2.6.9.1=mailto:rajeev@centraltrusts.org.in,
postalCode=600034, st=TAMIL NADU,
serialNumber=15715B47A24696E5F6E3BCD9C
02DD01E733FA12A1112BE9AF8F70104A1
9013; cn=RAJEEV SINGH RAGHUVAHSNI
Date: 2023.10.23 14:35:57 +05'30'

Stamp

Note: The permission to initiate clinical trial granted under rule 22 in form CT-06 shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Annexure:

Details of new drug or investigational new drug:

Names of the new drug or investigational new drug	IcoSema 700 U/ml + 2 mg/ml (Insulin Icodec 700U/ml + Semaglutide 2.0 mg/ml)
Therapeutic class:	Anti-diabetic
Dosage form:	Solution for injection
Composition:	<p>Drug substance: Quantity per ml</p> <p>Insulin Icodec - 4200 nmol (700 U)</p> <p>Semaglutide - 2.0 mg</p> <p>Excipients:</p> <p>Zinc (as Zinc acetate) - 101µg</p> <p>Glycerol - 15 mg</p> <p>Phenol - 5.65 mg (60 mM)^A</p> <p>Metacresol - 1.08 mg (10 mM)^A</p> <p>Sodium chloride- 1.17 mg (20 mM)</p> <p>HCl - q.s.^B</p>

File No. CT/56/23-DCG(I)

	NAOH - q.s. ^B Water For Injection (WFI)- To 1.00 ml pH - 7.4
Indications:	Type 2 diabetes inadequately controlled on oral anti-diabetic drugs

^A An average of 3% is added to compensate for loss during manufacture.

^B For pH adjustment.

Annexure:

Details of clinical trial site:

Sr. No.	Names and address of clinical trial site	Ethics committee details	Name of investigator
1	Seth G. S. Medical college and KEM Hospital, Acharya Donde Marg, Parel, Mumbai- 400012, Maharashtra India.	Institutional Ethics Committee (IEG- I), New UG/PG Hostel, 20 storey Hostel building, Ground floor, KEM Hospital campus, near main boys Hostel, Dr. S.S. Rao Marg, Parel Mumbai 400012, India. ECR/229/Inst/MH/2013/RR-19	Dr. Tushar Ramkrishna Bandgar
2	Madras Diabetes Research Foundation, No. 4, Conran Smith Road, Gopalpuram, Chennai- 600086	Institutional Ethics committee of Madras Diabetes Research Foundation, No- 4, Conran Smith Road, Gopalapuram Chennai- 600086 ECR/194/Inst/TN/2013/RR-19	Dr. V Mohan
3	Department of Endocrinology, Nehru Hospital Extension Block, Ground floor, Room No. 008, Post Graduate Institute Of Medical Education & Research, (PGIMER) Sector- 12, Chandigarh- 160012	Institutional Ethics Committee Room No 6006, Sixth floor, IEC office, PN Chuttani Block, Post Graduate Institute of Medical Education and Research (PGIMER), Sector 12. Chandigarh-160012 ECR/25/Inst/CH/2013/RR-20	Dr. Sanjay Kumar Bhadada
4	Department of Endocrinology, IPGME&R/SSKM Hospital, 244, AJC Bose Road, Kolkata- 700020, West Bengal	IPGME&R Research Oversight Committee, 244, AJC Bose Road, Kolkata- 700020 ECR/35/Inst/WB/2013/RR-19	Dr. Sujoy Ghosh
5	M S Ramaiah Medical College and Hospitals, MS Ramaiah Nagar, MSRIT Post, Bangalore- 560054, Karnataka India.	Ethics Committee, : M S Ramaiah Medical College and Hospitals, M S Ramaiah Nagar, MSRIT Post, Bangalore- 560054, Karnataka, India ECR/215/Inst/KA/2013/RR-22	Dr Pramila Kalra

File No. CT/56/23-DCG(I)

6	B.S.E.S Municipal General Hospital, S.V. Road, Opp. Railway Station, Andheri (West), Mumbai- 400058	BSES Municipal General Hospital Ethics Committee, Second Floor, Brahma Kumaris Global Hospital & Research Centre, BSES Municipal General Hospital, S.V. Road, Andheri (W), Mumbai-400058, India ECR/343/Inst/MH/2013/RR-19	Dr. Chawla Manoj Satesh
7	Department of Endocrinology, 4th floor, Room No 419, College Building, T.N. Medical College and B.Y.L. Nair Charitable Hospital, Dr. A.L. Nair Road, Mumbai- 400008	Institutional Ethics Committee 'G' building, Ground floor, B.Y.L. Nair Ch. Hospital, Dr. A. L. Nair Road, Mumbai 400008 ECR/22/Inst/Maha/2013/RR-19	Dr. Nikhil Madhusudan Bhagwat
8	Department of Medicine, K R Hospital attached to Mysore Medical College and Research Institute, Irwin Road, Mysore- 570001	Institutional Ethics Committee- Mysore Medical College and Research Institute and Associated Hospitals, Department of Pathology, KR Hospital, Mysore Medical College and Research Institute, Irwin Road, Mysore- 570001, Karnataka India. ECR/134/Inst/KA/2013/RR-19	Dr. Sumaiya Anjum
9	Chellaram Diabetes Institute, "Lalani Quantum", Pune- Bangalore National Highway No. 4, opp. Calsoft Building, Bavdhan (Budruk), Pune, Maharashtra — 411021.	Chellaram Diabetes Institute- Institutional Ethics Committee, "Lalani Quantum", Pune- Bangalore National Highway No. 4, opp. Calsoft Building, Bavdhan (Budruk), Pune, Maharashtra — 411021 ECR/203/Inst/MH/2014/RR-20	Dr Unnikrishnan A.G
